Catabasis Pharmaceuticals adds Gregg Lapointe to its Board of Directors

– USA, MA –  Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors.

Mr. Lapointe has three decades of commercial and financial experience and he is Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases.

“Gregg’s broad set of experiences as a leader and a director makes him an excellent addition to our board of directors,” said Ken Bate, co-Chairman of Catabasis’ Board of Directors. “His past roles involving commercial operations and rare diseases will be very valuable as we move through Phase 3 and prepare for a commercial launch of our lead program edasalonexent.”

About Gregg Lapointe

Mr. Lapointe currently serves on the Board of Directors of Cytori Therapeutics, Inc., Soligenix, Inc., and Rigel Pharmaceuticals, Inc. Prior to founding Cerium Pharmaceuticals, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a private biopharmaceutical company, from 2008 to 2012 as well as Chief Operating Officer from 2003 to 2008. Mr. Lapointe holds a Bachelor of Commerce from Concordia University (Montreal), a graduate diploma in Accountancy from McGill University (Montreal), an MBA from Duke University and is a CPA (Illinois).

“I am incredibly excited at the potential for edasalonexent to have a significant impact on the treatment landscape for Duchenne muscular dystrophy, and I look forward to contributing my expertise as Catabasis prepares to bring this novel therapy to all that could benefit,” said Gregg Lapointe.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne.
For more, visit www.catabasis.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.